The National Institute for Health and Care Excellence (NICE) committee cited a lack of evidence for esketamine's efficacy compared to standard therapies, uncertainty regarding the sustainability of its benefits, and high costs as reasons for recommending against its public-payer adoption.

Authors

• Person: Not available Organization: Frontiers in Psychiatry
  The Montreal model: an integrative biomedical-psychedelic ...

Sources

• The Montreal model: an integrative biomedical-psychedelic ... www.frontiersin.org Frontiers in Psychiatry via serper

Referenced by nodes (2)

• esketamine concept
• National Institute for Health and Care Excellence entity